TENOFOVIR DISOPROXIL FUMARATE = TDF oral

Select language:
Permalink
On this page

    Last updated: November 2022

     

    Prescription under medical supervision

     

    Therapeutic action

    • Antiretroviral, HIV nucleotide reverse transcriptase inhibitor 

    Indications

    • HIV infection with or without chronic hepatitis B coinfection, in combination with other antiretrovirals 
    • Chronic hepatitis B without HIV coinfection, in monotherapy

    Forms and strengths

    • 300 mg tablet, equivalent to 245 mg of tenofovir disoproxil

    Dosage

    • Child 35 kg and over and adult: 300 mg once daily

    Duration

    • Depending on the efficacy and tolerance of tenofovir.

    Contra-indications, adverse effects, precautions

    • Administer with caution and monitor use in patients with renal impairment, osteoporosis. In the event of deterioration of renal function, switch to another antiretroviral.
    • Avoid combination (or monitor renal function in the event of combination) with nephrotoxic drugs: aminoglycosides (e.g. gentamicin, streptomycin), amphotericin B, pentamidine, NSAIDs, etc.
    • May cause:
      • gastrointestinal disturbances (nausea, vomiting, diarrhoea, etc.), dizziness, fatigue, skin rash;
      • renal impairment, bone loss (osteoporosis, fractures), pancreatitis.
    • Pregnancy: no contra-indication

    Remarks

    • Tenofovir is also used for HIV pre-exposure and post-exposure prophylaxis, in combination with other antiretrovirals.
    • Also comes in fixed-dose combinations containing tenofovir and other antiretrovirals for the treatment of HIV infection. Preferably use these formulations when available.

    Storage

     
    –  
     
    –  Below 25 °C